Cochlear (OC5) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OC5 Analyst Ratings

Hold

0 Buy

6 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Cochlear

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OC5 Stock 12 Month Forecast

Average Price Target

€72.02

▼(-3.80% Downside)

Based on 7 Wall Street analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is €72.02 with a high forecast of €81.49 and a low forecast of €61.27. The average price target represents a -3.80% change from the last price of €74.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"€57","172":"€172","85.75":"€85.8","114.5":"€114.5","143.25":"€143.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":81.487903,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€81.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.01745068571428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€72.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.2691,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€61.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,85.75,114.5,143.25,172],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.44,72.21291561538462,72.98583123076924,73.75874684615384,74.53166246153846,75.30457807692308,76.0774936923077,76.8504093076923,77.62332492307692,78.39624053846154,79.16915615384616,79.94207176923076,80.71498738461538,{"y":81.487903,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.44,71.48441928351649,71.52883856703296,71.57325785054945,71.61767713406593,71.66209641758242,71.7065157010989,71.75093498461538,71.79535426813186,71.83977355164835,71.88419283516482,71.92861211868131,71.97303140219779,{"y":72.01745068571428,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.44,70.65762307692307,69.87524615384615,69.09286923076922,68.3104923076923,67.52811538461539,66.74573846153847,65.96336153846154,65.18098461538462,64.39860769230769,63.61623076923077,62.83385384615384,62.051476923076926,{"y":61.2691,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":166.323,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.245,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.186,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.228,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 62, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.194,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.241,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.485,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":154.683,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 56, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.244,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 83, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.44,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€81.49

Average Price Target€72.02

Lowest Price Target€61.27

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Stanton

Jefferies

€78.67

Hold

5.09%

Upside

Downgraded

07/28/26

Cochlear (CHEOF) was downgraded to a Hold Rating at Jefferies

Chris Cooper

J.P. Morgan

€68.01→€73.16

Hold

-2.28%

Downside

Reiterated

07/21/26

Cochlear (CHEOF) Receives a Hold from J.P. Morgan

Craig Wong-Pan

RBC Capital

€76.59→€71.68

Hold

-4.24%

Downside

Downgraded

07/16/26

RBC Capital downgrades Cochlear (CHEOF) to a Hold

David Low

UBS

€64.95

Hold

-13.24%

Downside

Reiterated

07/15/26

Cochlear (CHEOF) Gets a Hold from UBS

Laura Sutcliffe

Citi

€58.21→€61.27

Sell

-18.16%

Downside

Reiterated

07/13/26

Citi Remains a Sell on Cochlear (CHEOF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

€94.35→€81.49

Hold

8.85%

Upside

Reiterated

07/02/26

Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

€70.46→€72.91

Hold

-2.60%

Downside

Reiterated

06/30/26

Macquarie Remains a Hold on Cochlear (CHEOF)

Shane Storey

Canaccord Genuity

€180.74→€73.52

Buy

-1.79%

Downside

Reiterated

04/29/26

Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)

David Bailey

Morgan Stanley

€118.86→€72.91

Hold

-2.60%

Downside

Upgraded

04/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)

Derek Jellinek

Morgans

€131.69→€65.66

Hold

-12.29%

Downside

Reiterated

04/23/26

Cochlear (CHEOF) Gets a Hold from Morgans

Steven Wheen

Jarden

€137.24→€103.54

Hold

38.32%

Upside

Reiterated

04/22/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€150.05→€132.22

Hold

76.62%

Upside

Reiterated

03/13/26

Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Stanton

Jefferies

€78.67

Hold

5.09%

Upside

Downgraded

07/28/26

Cochlear (CHEOF) was downgraded to a Hold Rating at Jefferies

Chris Cooper

J.P. Morgan

€68.01→€73.16

Hold

-2.28%

Downside

Reiterated

07/21/26

Cochlear (CHEOF) Receives a Hold from J.P. Morgan

Craig Wong-Pan

RBC Capital

€76.59→€71.68

Hold

-4.24%

Downside

Downgraded

07/16/26

RBC Capital downgrades Cochlear (CHEOF) to a Hold

David Low

UBS

€64.95

Hold

-13.24%

Downside

Reiterated

07/15/26

Cochlear (CHEOF) Gets a Hold from UBS

Laura Sutcliffe

Citi

€58.21→€61.27

Sell

-18.16%

Downside

Reiterated

07/13/26

Citi Remains a Sell on Cochlear (CHEOF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

€94.35→€81.49

Hold

8.85%

Upside

Reiterated

07/02/26

Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

€70.46→€72.91

Hold

-2.60%

Downside

Reiterated

06/30/26

Macquarie Remains a Hold on Cochlear (CHEOF)

Shane Storey

Canaccord Genuity

€180.74→€73.52

Buy

-1.79%

Downside

Reiterated

04/29/26

Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)

David Bailey

Morgan Stanley

€118.86→€72.91

Hold

-2.60%

Downside

Upgraded

04/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)

Derek Jellinek

Morgans

€131.69→€65.66

Hold

-12.29%

Downside

Reiterated

04/23/26

Cochlear (CHEOF) Gets a Hold from Morgans

Steven Wheen

Jarden

€137.24→€103.54

Hold

38.32%

Upside

Reiterated

04/22/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€150.05→€132.22

Hold

76.62%

Upside

Reiterated

03/13/26

Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cochlear

3 Months

Shane StoreyCanaccord Genuity

Success Rate

5/9 ratings generated profit

Average Return

-3.96%

reiterated a buy rating 3 months ago

Copying Shane Storey's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -3.96% per trade.

1 Year

Shane StoreyCanaccord Genuity

Success Rate

2/9 ratings generated profit

Average Return

-20.68%

reiterated a buy rating 3 months ago

Copying Shane Storey's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -20.68% per trade.

2 Years

Shane StoreyCanaccord Genuity

Success Rate

2/9 ratings generated profit

Average Return

-22.83%

reiterated a buy rating 3 months ago

Copying Shane Storey's trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -22.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OC5 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OC5 has received 8 Buy Ratings, 49 Hold Ratings, and 1 Sell Ratings. OC5 average Analyst price target in the past 3 months is 72.02.

Each month's total comprises the sum of three months' worth of ratings.

OC5 Financial Forecast

OC5 Earnings Forecast

Next quarter’s earnings estimate for OC5 is €1.04 with a range of €0.74 to €1.15. The previous quarter’s EPS was €1.81. OC5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Sales Forecast

Next quarter’s sales forecast for OC5 is €710.44M with a range of €684.25M to €744.25M. The previous quarter’s sales results were €712.74M. OC5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Stock Forecast FAQ

What is DE:OC5’s average 12-month price target, according to analysts?

Based on analyst ratings, Cochlear Limited’s 12-month average price target is 72.02.

What is DE:OC5’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:OC5, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Cochlear Limited a Buy, Sell or Hold?

Cochlear Limited has a consensus rating of Hold, which is based on 0 buy ratings, 6 hold ratings and 1 sell ratings.

What is Cochlear Limited’s share price target?

The average share price target for Cochlear Limited is 72.02. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €81.49 ,and the lowest forecast is €61.27. The average share price target represents -3.80% Decrease from the current price of €74.86.

What do analysts say about Cochlear Limited?

Cochlear Limited’s analyst rating consensus is a Hold. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Cochlear Limited?

To buy shares of DE:OC5, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Cochlear (OC5) Stock Forecast & Price Target

OC5 Analyst Ratings

OC5 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cochlear

OC5 Analyst Recommendation Trends

OC5 Financial Forecast

OC5 Earnings Forecast

OC5 Sales Forecast

OC5 Stock Forecast FAQ

Detailed List of Analyst Forecasts